DiscGenics, Inc. (DiscGenics) announces the allowance of 9 additional patents that expand its intellectual property portfolio within both the U.S. and globally to 24 issued patents. The new patents include 2 in the U.S. and 7 in key European markets.

DiscGenics, Inc. (DiscGenics) announces that the company has been selected as a Global Innovations Partner by Cavendish Global.

DiscGenics, a biotechnology company developing off-the-shelf cell therapies for back pain, announced today that it has been selected as a winner of Red Herring's Top 100 North America Award. 

DiscGenics is honored to announce that it was one of three Biotech finalist for the 12th annual Utah Innovation Awards.  The finalists were chosen by 60 industry experts and professionals from the Utah’s business, government, and higher educations communities.

DiscGenics, Inc. (DiscGenics) announced today that its initial patent has been granted in four key international markets including Europe, Japan, China, and Israel. The issuance of this patent abroad extends the protection of the company's domestic intellectual property (IP) into major international markets. The European patent has also been validated in the key strategic European countries. Additional applications in other key global markets are pending to ensure broad coverage of DiscGenics' IP.